论文部分内容阅读
目的:研究清肝化瘀方联合TACE术对原发性肝癌的临床疗效。方法:依据随机数字法将2015年7月~2016年8月重庆市肿瘤医院收治的76例原发性肝癌病例分为2组,各38例,对照组采取TACE术与术后常规治疗措施,实验组基于对照组予以清肝化瘀方,比较2组患者治疗前后甲胎蛋白(AFP)水平、肝功能、细胞免疫功能、中医症候积分及疗效。结果:实验组实体瘤总缓解率为36.84%,明显高于对照组15.79%(P<0.05);实验组AFP水平与中医症候积分均明显低于对照组(P<0.05);实验组AST、ALT、IL-12、TNF-α浓度明显低于对照组(P<0.05),且ALB、IL-2浓度明显高于对照组(P<0.05)。结论:清肝化瘀方联合TACE术可对原发性肝癌患者肿瘤生长产生有效抑制作用,提高其肝功能与免疫能力,减少AFP,改善临床症状,疗效显著。
Objective: To study the clinical curative effect of Qinggan Huayu decoction combined with TACE on primary liver cancer. Methods: According to the random number method, 76 cases of primary hepatocellular carcinoma treated in Chongqing Tumor Hospital from July 2015 to August 2016 were divided into two groups (38 cases each). The control group received TACE and conventional postoperative treatment, The experimental group was given Qinggan Huayu prescription based on the control group. The levels of AFP, liver function, cellular immune function, TCM symptom score and therapeutic effect were compared between the two groups before and after treatment. Results: The total remission rate of solid tumors in experimental group was 36.84%, which was significantly higher than that in control group (15.79%, P <0.05). The AFP level and TCM symptom score in experimental group were significantly lower than those in control group (P <0.05) The concentrations of ALT, IL-12 and TNF-α were significantly lower than those of the control group (P <0.05), and the concentrations of ALB and IL-2 were significantly higher than those of the control group (P <0.05). Conclusion: Qinggan Huayu decoction combined with TACE can effectively inhibit tumor growth in patients with primary liver cancer, improve liver function and immunity, reduce AFP, and improve clinical symptoms.